Previous close | 10.75 |
Open | 10.66 |
Bid | 10.71 x 600 |
Ask | 10.76 x 600 |
Day's range | 10.56 - 11.12 |
52-week range | 8.12 - 43.69 |
Volume | |
Avg. volume | 1,028,506 |
Market cap | 385.452M |
Beta (5Y monthly) | -0.54 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Biomea Fusion (BMEA) rises 41% in a month on the back of positive investor expectations regarding the clinical development of its lead candidate, BMF-219, for the type II diabetes indication.
Biomea (BMEA) successfully doses the first patient in its phase I study of BMF-500 to treat adult patients with acute leukemia. The company's stock rises 6.7% on the news.